ATE384793T1 - Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen - Google Patents

Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen

Info

Publication number
ATE384793T1
ATE384793T1 AT00962125T AT00962125T ATE384793T1 AT E384793 T1 ATE384793 T1 AT E384793T1 AT 00962125 T AT00962125 T AT 00962125T AT 00962125 T AT00962125 T AT 00962125T AT E384793 T1 ATE384793 T1 AT E384793T1
Authority
AT
Austria
Prior art keywords
dna fragments
corresponding dna
chlamydia antigens
chlamydia
strain
Prior art date
Application number
AT00962125T
Other languages
English (en)
Inventor
Andrew Murdin
Raymond Oomen
Joe Wang
Pamela Dunn
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Application granted granted Critical
Publication of ATE384793T1 publication Critical patent/ATE384793T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT00962125T 1999-09-20 2000-09-15 Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen ATE384793T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15465299P 1999-09-20 1999-09-20

Publications (1)

Publication Number Publication Date
ATE384793T1 true ATE384793T1 (de) 2008-02-15

Family

ID=22552195

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00962125T ATE384793T1 (de) 1999-09-20 2000-09-15 Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen

Country Status (9)

Country Link
US (2) US7314869B2 (de)
EP (1) EP1220925B8 (de)
JP (1) JP4667694B2 (de)
AT (1) ATE384793T1 (de)
AU (1) AU783547B2 (de)
CA (1) CA2385325C (de)
DE (1) DE60037900T2 (de)
NZ (1) NZ517952A (de)
WO (1) WO2001021804A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
EP1105489A1 (de) 1998-08-20 2001-06-13 Aventis Pasteur Limited Nukleinsäuren kodierend für pomp91a aus chlamydia
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
AU3790900A (en) 1998-12-01 2000-06-19 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
MXPA01005615A (es) * 1998-12-04 2004-08-19 Univ Manitoba Procedimiento de inmunizacion en dos pasos para proteger contra infeccion por chlamydia.
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
CN100365120C (zh) 1998-12-08 2008-01-30 科里克萨有限公司 用于治疗及诊断衣原体感染的化合物和方法
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
JP2002541766A (ja) 1998-12-28 2002-12-10 アベンティス、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
EP2172214A3 (de) 1999-03-12 2011-03-16 Aventis Pasteur Limited Chlamydia-Antigene und entsprechende DNA-Fragmente sowie Verwendungen davon
WO2000066739A2 (en) 1999-05-03 2000-11-09 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
CA2385325C (en) 1999-09-20 2012-04-10 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
EP1240331B1 (de) 1999-12-22 2010-04-07 Aventis Pasteur Limited Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
AU2001255596A1 (en) 2000-04-21 2001-11-07 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP1282718B1 (de) 2000-05-08 2006-12-20 Sanofi Pasteur Limited Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
WO2005049836A1 (en) * 2003-11-21 2005-06-02 Aventis Pasteur Limited Immunization against chlamydia infection
WO2010100632A2 (en) 2009-03-06 2010-09-10 Novartis Ag Chlamydia antigens

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002546A2 (en) 1996-07-12 1998-01-22 University Of Manitoba Dna immunization against chlamydia infection
US6579854B1 (en) * 1996-08-14 2003-06-17 Vanderbilt University Diagnosis and management of infection caused by chlamydia
ES2264810T3 (es) * 1997-06-23 2007-01-16 Loke Diagnostics Aps Proteinas de chlamydia pneumoniae expuestas en la superficie.
ATE480625T1 (de) 1997-11-21 2010-09-15 Merck Serono Biodevelopment Äusseres membranpolypeptid von chlamydia pneumoniae sowie fragmente davon und deren verwendung, insbesondere zur diagnose, prävention und behandlung einer infektion
KR20010032336A (ko) * 1997-11-21 2001-04-16 브랑디 빠스깔 클라미디아 뉴모니아 게놈 서열과 폴리펩티드, 이의 단편및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
KR100760221B1 (ko) 1997-11-28 2007-10-30 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
EP1129202A2 (de) 1998-10-28 2001-09-05 Aventis Pasteur Limited Chlamydia polypeptiden und entspechende dna fragmenten und anwendungen davon
US6822071B1 (en) 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
EP1133572A4 (de) 1998-11-12 2005-06-15 Univ California Genomsequenz von chlamydia pneumoniae
AU3790900A (en) 1998-12-01 2000-06-19 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
CN100365120C (zh) 1998-12-08 2008-01-30 科里克萨有限公司 用于治疗及诊断衣原体感染的化合物和方法
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
WO2000066739A2 (en) 1999-05-03 2000-11-09 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
CA2385325C (en) 1999-09-20 2012-04-10 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
EP1240331B1 (de) 1999-12-22 2010-04-07 Aventis Pasteur Limited Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
AU2138501A (en) 1999-12-22 2001-07-03 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US20030100706A1 (en) 2000-04-04 2003-05-29 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020071831A1 (en) 2000-04-04 2002-06-13 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020094965A1 (en) 2000-04-04 2002-07-18 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020082402A1 (en) 2000-04-04 2002-06-27 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020132994A1 (en) 2000-04-04 2002-09-19 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
AU2001255596A1 (en) 2000-04-21 2001-11-07 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP1282718B1 (de) 2000-05-08 2006-12-20 Sanofi Pasteur Limited Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
US20040254130A1 (en) 2000-05-08 2004-12-16 Murdin Andrew D Chlamydia antigens and corresponding dna fragments and uses thereof
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae

Also Published As

Publication number Publication date
CA2385325C (en) 2012-04-10
US7662391B2 (en) 2010-02-16
JP2003510050A (ja) 2003-03-18
AU783547B2 (en) 2005-11-10
JP4667694B2 (ja) 2011-04-13
US20050002944A1 (en) 2005-01-06
US7314869B2 (en) 2008-01-01
NZ517952A (en) 2004-01-30
WO2001021804B1 (en) 2001-05-10
CA2385325A1 (en) 2001-03-29
EP1220925B8 (de) 2008-04-23
WO2001021804A1 (en) 2001-03-29
US20050220805A1 (en) 2005-10-06
EP1220925B1 (de) 2008-01-23
DE60037900T2 (de) 2009-02-12
EP1220925A1 (de) 2002-07-10
DE60037900D1 (de) 2008-03-13
AU7398500A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
DE60037900D1 (de) Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen
ATE463575T1 (de) Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
ATE375391T1 (de) Chlamydia-antigene und entsprechende dna- fragmente und deren verwendungen
IL211037A (en) Antigen @ reactant @ with @ serum @ hyper
DK1292328T3 (da) Kimære humant papillomvirus- (HPV) - molekyler og deres anvendelse
WO2003049762A3 (en) Immunisation against chlamydia trachomatis
ATE440861T1 (de) Immunisierung gegen chlamydia pneumoniae
ATE500843T1 (de) Streptococcus pneumoniae proteine und impfstoffe
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
DE60144201D1 (de) Lawsonia intracellularis Impfstoff
AU2003242535A1 (en) Improved polysaccharide and glycoconjugate vaccines
DE60336927D1 (de)
WO2001046225A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
ATE417106T1 (de) Chlamydia antigene und deren korrespondierende dna fragmente und verwendungen davon
EE200200157A (et) Vaktsiin
WO2001046226A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
BR0207447A (pt) Polipeptìdeos e fragmentos de dna correspondentes de streptococcus pyogenes úteis como componentes de vacina
WO2005048918A3 (en) Anthrax vaccine
DK1227840T3 (da) Adjuverede, genetiske vacciner
WO2004073604A3 (en) Dna vaccines that express an adp-ribosyltransferase toxin devoid of adp-ribosyltransferase activity
DE60234772D1 (de) Gruppe-b streptococcus antigene und entsprechende dna-fragmente
WO2001036455A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2000006743A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001036457A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO1998046742A3 (de) Dictyocaulus viviparus antigen zur diagnose des lungenwurmbefalls und zur vakzinierung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1220925

Country of ref document: EP